Articles

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Spain
St. István, St. László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Medical University of Lublin and St John’s Cancer Center, Lublin, Poland
Skåne University Hospital, Lund University, Sweden
University of Alberta Edmonton, Canada
University Hospital Brno, Czech Republic
Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial (IPOPFG, EPE), Portugal
Middlemore Hospital, Auckland, New Zealand
Institut Paoli-Calmettes, Marseille, France
University Hospital Rigshospitalet, Copenhagen, Denmark
Medical College of Wisconsin, Milwaukee, WI, USA
Spitalul Clinic Coltea, Bucharest, Romania
Millennium Pharmaceuticals Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
Millennium Pharmaceuticals Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
Millennium Pharmaceuticals Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
Millennium Pharmaceuticals Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
Dana-Farber Cancer Institute, Boston, MA, USA
University Hospital Hôtel Dieu, Nantes, France
Vol. 102 No. 10 (2017): October, 2017 https://doi.org/10.3324/haematol.2017.170118